Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC
In the PRO analyses of the phase III CodeBreak 200 trial, the first-in-class KRASG12C inhibitor sotorasib improved quality of life (QoL) of patients with pretreated KRASG12C-mutated advanced non-small-cell lung cancer (NSCLC) compared with docetaxel.
Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC
19 Jun 2023
Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD
Among women with inflammatory bowel disease (IBD), those who have long-term immunomodulator exposure are at increased risk of high-grade cervical intraepithelial neoplasia and cervical cancer (CIN2+), according to a study.
Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD
16 Jun 2023
Ribociclib plus endocrine therapy: A win for early breast cancer?
In the second interim efficacy analysis of the phase III NATALEE trial, a combination regimen comprising the CDK4/6 inhibitor ribociclib and endocrine therapy (ET) demonstrated favourable signals for the adjuvant treatment of stage II/III hormone receptor-positive, HER2-negative (HR+, HER2–) early breast cancer.